The CDC intends to award a sole-source, firm-fixed-price contract to Biosearch Technologies Inc. in Petaluma, CA, for the manufacture of GMP Influenza A Primer Kits. The purpose is to obtain specifically designed oligonucleotide reagents that meet GMP quality standards to support influenza genomic surveillance. While this is a planned sole-source action to Biosearch Technologies, firms that believe they can meet the requirement are encouraged to submit a capability statement. Any such statement must be submitted in writing to the specified contract specialist by February 9, 2026. The government will consider responses solely to determine if a competitive procurement is warranted.